Compare CRTO & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | IVA |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | France | France |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 1.1B |
| IPO Year | 2013 | 2020 |
| Metric | CRTO | IVA |
|---|---|---|
| Price | $17.24 | $4.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $34.00 | $16.20 |
| AVG Volume (30 Days) | 467.3K | ★ 654.9K |
| Earning Date | 05-06-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,296,692,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.54 | $751.20 |
| P/E Ratio | $45.86 | ★ N/A |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $15.58 | $3.35 |
| 52 Week High | $25.29 | $7.98 |
| Indicator | CRTO | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 62.61 |
| Support Level | $16.36 | $4.86 |
| Resistance Level | $19.55 | $4.94 |
| Average True Range (ATR) | 0.74 | 0.16 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 24.55 | 84.91 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.